Progress and Prospects of Anti-HBV Gene Therapy Development.

ABSTRACT: Despite the availability of an effective vaccine against hepatitis B virus (HBV), chronic infection with the virus remains a major global health concern. Current drugs against HBV infection are limited by emergence of resistance and rarely achieve complete viral clearance. This has prompted vigorous research on developing better drugs against chronic HBV infection. Advances in understanding the life cycle of HBV and improvements in gene-disabling technologies have been impressive. This has led to development of better HBV infection models and discovery of new drug candidates. Ideally, a regimen against chronic HBV infection should completely eliminate all viral replicative intermediates, especially covalently closed circular DNA (cccDNA). For the past few decades, nucleic acid-based therap

SUBMITTER: Maepa MB 

PROVIDER: S-EPMC4581210 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature